Logo image of GLSI

GREENWICH LIFESCIENCES INC (GLSI) Stock Price, Quote, News and Overview

NASDAQ:GLSI - Nasdaq - US3968791083 - Common Stock - Currency: USD

9.7  +0.36 (+3.85%)

GLSI Quote, Performance and Key Statistics

GREENWICH LIFESCIENCES INC

NASDAQ:GLSI (6/5/2025, 12:49:59 PM)

9.7

+0.36 (+3.85%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High18.75
52 Week Low8.06
Market Cap129.69M
Shares13.37M
Float6.11M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-12 2025-08-12
IPO09-25 2020-09-25


GLSI short term performance overview.The bars show the price performance of GLSI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30

GLSI long term performance overview.The bars show the price performance of GLSI in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 10 -10 -20 -30

The current stock price of GLSI is 9.7 USD. In the past month the price decreased by -0.43%. In the past year, price decreased by -35.05%.

GREENWICH LIFESCIENCES INC / GLSI Daily stock chart

GLSI Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.26 331.17B
AMGN AMGEN INC 13.95 155.69B
GILD GILEAD SCIENCES INC 14.45 139.10B
VRTX VERTEX PHARMACEUTICALS INC N/A 114.37B
REGN REGENERON PHARMACEUTICALS 11.01 52.65B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 39.91B
ARGX ARGENX SE - ADR 100.36 35.24B
ONC BEONE MEDICINES LTD-ADR 6.59 27.85B
BNTX BIONTECH SE-ADR N/A 26.59B
NTRA NATERA INC N/A 22.75B
BIIB BIOGEN INC 8.3 19.23B
SMMT SUMMIT THERAPEUTICS INC N/A 14.65B

About GLSI

Company Profile

GLSI logo image Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company is headquartered in Stafford Texas, Texas and currently employs 4 full-time employees. The company went IPO on 2020-09-25. The firm is focused on the development of GP2, immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9 amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2)/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer. The company has commenced a Phase III clinical trial, Flamingo-01 an immunotherapy to prevent breast cancer recurrences.

Company Info

GREENWICH LIFESCIENCES INC

3992 Bluebonnet Dr, Building 14

Stafford Texas TEXAS 33954 US

CEO: Snehal Patel

Employees: 6

GLSI Company Website

GLSI Investor Relations

Phone: 12034343290

GREENWICH LIFESCIENCES INC / GLSI FAQ

What is the stock price of GREENWICH LIFESCIENCES INC today?

The current stock price of GLSI is 9.7 USD. The price increased by 3.85% in the last trading session.


What is the ticker symbol for GREENWICH LIFESCIENCES INC stock?

The exchange symbol of GREENWICH LIFESCIENCES INC is GLSI and it is listed on the Nasdaq exchange.


On which exchange is GLSI stock listed?

GLSI stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for GREENWICH LIFESCIENCES INC stock?

7 analysts have analysed GLSI and the average price target is 39.78 USD. This implies a price increase of 310.1% is expected in the next year compared to the current price of 9.7. Check the GREENWICH LIFESCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is GREENWICH LIFESCIENCES INC worth?

GREENWICH LIFESCIENCES INC (GLSI) has a market capitalization of 129.69M USD. This makes GLSI a Micro Cap stock.


How many employees does GREENWICH LIFESCIENCES INC have?

GREENWICH LIFESCIENCES INC (GLSI) currently has 6 employees.


What are the support and resistance levels for GREENWICH LIFESCIENCES INC (GLSI) stock?

GREENWICH LIFESCIENCES INC (GLSI) has a support level at 8.9 and a resistance level at 9.7. Check the full technical report for a detailed analysis of GLSI support and resistance levels.


Should I buy GREENWICH LIFESCIENCES INC (GLSI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does GREENWICH LIFESCIENCES INC (GLSI) stock pay dividends?

GLSI does not pay a dividend.


When does GREENWICH LIFESCIENCES INC (GLSI) report earnings?

GREENWICH LIFESCIENCES INC (GLSI) will report earnings on 2025-08-12.


What is the Price/Earnings (PE) ratio of GREENWICH LIFESCIENCES INC (GLSI)?

GREENWICH LIFESCIENCES INC (GLSI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.26).


What is the Short Interest ratio of GREENWICH LIFESCIENCES INC (GLSI) stock?

The outstanding short interest for GREENWICH LIFESCIENCES INC (GLSI) is 16.5% of its float. Check the ownership tab for more information on the GLSI short interest.


GLSI Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

GLSI Fundamental Analysis

ChartMill assigns a fundamental rating of 1 / 10 to GLSI. The financial health of GLSI is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

GLSI Financial Highlights

Over the last trailing twelve months GLSI reported a non-GAAP Earnings per Share(EPS) of -1.26. The EPS decreased by -74.08% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -602.52%
ROE -1262.97%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-31.58%
Sales Q2Q%N/A
EPS 1Y (TTM)-74.08%
Revenue 1Y (TTM)N/A

GLSI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 83% to GLSI. The Buy consensus is the average rating of analysts ratings from 7 analysts.


Ownership
Inst Owners8.43%
Ins Owners55.06%
Short Float %16.5%
Short Ratio11.26
Analysts
Analysts82.86
Price Target39.78 (310.1%)
EPS Next Y20.1%
Revenue Next YearN/A